相关临床试验
26
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
7.7%
已完成
6
23.1%
尚未招募
7
26.9%
招募中
9
34.6%
终止
2
7.7%
暂无批准数据
- An 18-month clinical trial found intermittent fasting and continuous calorie restriction produced similar weight loss of about seven kilograms at six months in adults with obesity. - Participants using intermittent fasting did not feel they needed to constantly monitor eating or count calories, unlike those on calorie-restricted diets. - The calorie restriction group reported that conscious control over eating accounted for approximately 15% of their weight loss. - Researchers suggest intermittent fasting could provide an alternative for individuals who struggle with conventional dieting, supporting more personalized weight management strategies.
- Australia has initiated a groundbreaking clinical trial testing personalized mRNA vaccines for children with deadly brain cancers, targeting those with treatment-resistant tumors who have exhausted other therapeutic options. - The PaedNEO-VAX study will enroll approximately 70 children across eight hospitals, using genetic sequencing to create customized vaccines targeting individual cancer markers within eight weeks of enrollment. - The trial leverages mRNA technology proven in COVID-19 vaccines to train the immune system to attack specific tumor proteins, with promising adult results in pancreatic cancer and melanoma providing hope for pediatric applications. - Children will receive eight vaccine doses injected into the arm two weeks apart, followed by a booster shot, with researchers expecting to determine treatment response within 12 months of starting therapy.
- Australian researchers have developed a targeted immunotherapy approach for myelofibrosis, a rare blood cancer that disrupts healthy blood cell production and currently has no cure. - The study, published in Blood journal, identified two distinct therapeutic targets based on calreticulin mutation types, representing a world-first discovery in precision treatment approaches. - The research demonstrates a paradigm shift from symptom management to targeting abnormal disease-driving cells using precision immunology while sparing healthy tissue. - Further clinical development is needed before human trials can begin, but the findings offer potential for more effective and targeted treatments for this serious condition.
- A Cochrane review confirms that magnesium sulfate infusions given to women at risk of premature birth can prevent cerebral palsy in their babies. - The inexpensive treatment, costing approximately $6.50 per dose, has been recommended by the WHO since 2015 for women at risk of premature birth before 32 weeks. - A program in England demonstrated that widespread use of magnesium sulfate resulted in an estimated 385 fewer cases of cerebral palsy between 2018 and 2023. - Researchers call for increased global implementation and further studies to optimize the drug's administration, especially in low-resource settings.
